BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
  • Interviews
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
  • AI in Bio
  • Outsourced R&D
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence

  AI in Bio

The Quantum Drug Discovery Tracker

by BiopharmaTrend    •   updated on Nov. 17, 2026

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook    

Latest changes · November 16, 2026

  • First edition as a living tracker, replacing our February 2024 article. 10 companies added.
  • Roivant Discovery is now PsiThera, an independent company with a $47.5M Series A.
  • Zapata shut down in October 2024 and is back as Zapata Quantum after a $15M round.
  • Algorithmiq won the only Q4Bio prize awarded; the $5M grand prize went unclaimed.
  • XtalPi added a Pierre Fabre deal on November 9, 2026. Riverlane moved to the infrastructure note.

"Quantum" in drug discovery means two different things. Most companies use quantum mechanics: they calculate how electrons behave in a drug and its target, on ordinary GPUs and supercomputers. A smaller group writes software for quantum computers, machines that may one day do those calculations far better but cannot yet beat classical methods on a drug problem.

Both matter. Quantum-mechanical methods catch effects that standard molecular mechanics misses, such as charge transfer, covalent binding and metal chemistry, and they now feed machine-learning models with accurate training data. Quantum computing is the longer bet: if hardware scales, the hardest of these calculations become routine. This tracker covers both and labels every company by what it actually runs on.

The big story

The money and the prizes are going to different places. The largest deals sit with companies doing quantum mechanics on classical hardware: XtalPi's DoveTree deal is worth up to $5.99B and its June 2026 GPCR deal more than $400M. The biggest scientific milestones belong to quantum-computing firms: Algorithmiq's Q4Bio win and its advantage claim with IBM. But the Q4Bio $5M grand prize for provable quantum advantage stayed unclaimed, because the hardware does not exist yet.

When we first covered this field in February 2024, two companies were heading to the public markets. XtalPi listed in Hong Kong in June 2024 and has since become the deal leader. Zapata went public through a SPAC the same year, ceased operations in October 2024, and re-emerged in 2025 as Zapata Quantum on the OTC market.

The rest of the 2024 list split three ways. Some grew: Aqemia passed $100M in funding and Algorithmiq moved its headquarters to Milan. Some changed identity: Roivant's Silicon Therapeutics unit became PsiThera, and ProteinQure and Menten AI now describe themselves mainly as machine-learning companies. Some went quiet. Meanwhile a new wave arrived, from Kvantify and QMatter on the quantum-computing side to Ten63, Achira and QSimulate on the quantum-mechanics side.

 

 

Read this Pro article free

Subscribe to BiopharmaTrend Insider, our free biweekly briefing on what matters in tech and bio, and get one free Pro article every month, starting with this one.

See Pro plans

Insider arrives every two weeks, plus a short note when we publish a new deep dive. Unsubscribe anytime. Articles you unlock stay unlocked.

Already subscribed? Sign in here.

Topic: AI in Bio

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook    

You may also be interested to read:

Merging AI and Quantum Computing To Boost Drug Discovery
by Andrii Buvailo

 

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Outsourced R&D
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar
  • Sponsored Content

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.

Sign in or create an account